Regional Clinical Advice Response Service 02/07/21

For any COVID-19 vaccination related queries or to escalate an incident please contact: england.swcovid19-cars@nhs.net

Please note that going forward and in line with the RVOC and NVOC, RCARS will now operate between the hours of 8am and 6pm over the weekend.

**PLEASE SHARE WITH ALL RELEVANT STAFF INVOLVED WITH THE VACCINATION PROGRAMME**

**Contents:**


3. **Generic information: Shared learning: Screening incidents – FOR INFORMATION**

4. **Palivizumab Passive Immunisation Against Respiratory Syncytial Virus (RSV) in At Risk Pre-Term Infants**


This document has been updated with all amendments highlighted in yellow. Please find attached.

The purpose of this document is to clarify the process by which incidents and enquiries related to the COVID-19 vaccination programme are escalated and addressed, at both regional and national levels, and to describe the audit and governance process for this. This is not intended to replace existing local investigation and risk management processes, in accordance with NHS England’s Serious Incident framework.

NHS England and NHS Improvement

The product information for both the Pfizer and Moderna Covid-19 vaccines have been updated to reflect new information regarding Myocarditis and Pericarditis and are attached for your information.

**Generic information: Shared learning: Screening incidents – FOR INFORMATION**

Amanda Oates, an executive director of workforce at Mersey Care NHS Foundation Trust, recently gave a talk on ‘Just Culture’ and learning from incidents. The recording is available on YouTube. It lasts approximately 45 minutes and can be watched in instalments. In her talk Amanda refers to some free training modules and ‘Just Culture – The Movie’.

**Palivizumab Passive Immunisation Against Respiratory Syncytial Virus (RSV) in At Risk Pre-Term Infants**

Please find attached, document outlining the interim clinical commissioning position for passive immunisation with palivizumab against respiratory syncytial virus (RSV) in at-risk pre-term infants.

**Commissioning Position**

The proposal is: to extend passive immunisation against RSV with palivizumab in at risk pre-term infants in accordance with the criteria set out in this document.

Please read the attached document for full details.

**All COVID-19 vaccination queries and incidents should be directed to:**

[england.swcovid19-cars@nhs.net](mailto:england.swcovid19-cars@nhs.net)